A Phase 1 First-in-Human, dose-escalation study of CRB-601 monotherapy and in combination with PD-1
Latest Information Update: 13 May 2024
At a glance
- Drugs CRB-601 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 07 May 2024 According to a Corbus Pharmaceuticals media release, the company expects to initiate a Phase 1 study of CRB-601 in the summer of 2024
- 12 Mar 2024 According to a Corbus Pharmaceuticals media release, company expects to complete the CRB-601 Ph1 dose-escalation study (monotherapy and in combination with PD-1) by the end of 2024.
- 09 Jan 2024 According to a Corbus Pharmaceuticals media release, company has announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application of CRB-601. The Company expects to enroll the first participant in a Phase 1 study in the first half of 2024.